Controls | PAH | CTEPH | |
Subjects n | 7 | 9 | 9 |
Age yrs | 49 (43–63) | 53 (47–73) | 64 (48–80) |
Sex ratio male/female n | 3/4 | 5/4 | 5/4 |
NYHA I–II/III–IV n | 7/0 | 5/4 | 5/4 |
6MWT m | 505 (495–517) | 475 (347–530) | 442 (383–450) |
Pra mmHg | 4 (1–4) | 2 (1–3) | 6 (4–8) |
P̄pa mmHg | 18 (14–21) | 39 (32–50) | 36 (32–42) |
Ppa,syst mmHg | 34 (27–37) | 66 (51–80) | 60 (50–69) |
Ppa,diast mmHg | 14 (10–16) | 24 (21–32) | 20 (18–28) |
CI L·min−1·m−2 | 3.7 (2.8–4.0) | 2.4 (2.2–3.9) | 2.4 (2.2–2.6) |
PVRi UI·m−2 | 3.5 (2.3–3.7) | 10.2 (7.5–21.5) | 10.6 (6.1–14.7) |
Acute responder# n | 1 | 0 | |
Specific treatment for PAH at the time of RHC n | 3 | 2 |
Data are presented as median (interquartile range), unless otherwise stated. PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; NYHA: New York Heart Association; 6MWT: 6-min walk test; Pra: right atrial pressure; P̄pa: mean pulmonary artery pressure; Ppa,syst: systolic pulmonary artery pressure; Ppa,diast: diastolic pulmonary artery pressure; CI: cardiac index; PVRi: indexed pulmonary vascular resistance; RHC: right heart catheterisation. #: acute response to inhaled nitric oxide testing.